Mosaic Therapeutics has appointed Dr Barry Davies as its new CSO.
Dr Davies will now be responsible for leading the targeted oncology therapeutics company's scientific strategy, as well as its R&D team.
With more than 25 years of experience in the field of drug discovery, Barry will bring his wealth of knowledge in both preclinical and clinical trials to expand Mosaic's range of oncology therapeutics.
He has held high positions in AstraZeneca, with his most recent role being the Senior Director, Global Project Leader for the company.
During his time at the pharma giant, he led a number of projects across lead optimisation to phase II clinical trials, which mainly focused on cell signalling, apoptosis and DNA damage.
Mosaic Therapeutics' CEO, Magda Jonikas, commented: “Barry’s extensive experience and expertise in early oncology drug discovery and development will be a significant asset to Mosaic. His deep understanding of cancer biology and early drug development will be invaluable to the Company as we continue to progress our pipeline of targeted drug combinations in novel biomarker-defined settings, and enable us to deliver precision medicines for patients who currently have few therapeutic options.”
Barry Davies, CSO, Mosaic Therapeutics, commented: “Mosaic’s pedigree is impressive, and the potential of the data science platform coupled with deeply characterised preclinical models to identify new combination therapies within oncology is very exciting. I’m delighted to join the company at this pivotal stage and look forward to working with the leadership and scientific teams to drive the programmes forward.”
